Release Details

Details

Published on Tuesday, 22 July 2014 15:06

ABIVAX, NeoVacs, Valneva and the Institut Pasteur, the organizations associated in the FranceCellVax consortium, have announced the selection of their vaccine biotherapies project for treatment and prevention of inflammatory and infectious diseases, as a part of the “34 plans of the new industrial France” supported by the French Government. Over a period of five years, this project focuses on the industrial  and commercial development of innovative vaccines currently in clinical development for a marketing authorisation by 2020. The project also includes the use of worldwide immunotechnologic platforms intended for optimization of early stage clinical vaccine candidates. These platforms located in the Institut Pasteur, will be deployed in the context of FranceCellVax vaccine development.

The success of the FranceCellVax project is of crucial economic importance for France.The programs, all in clinical phase, have a potential global turnover of several billion euros, offering the possibility of huge future reinvestments on the national territory. The stake is major in terms of employment: the government support to those programs and FranceCellVax will increase the possibility to support the emergence of international leaders in innovative vaccine biotherapies in France.